GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity to manufacture messenger RNA vaccines – archyde

Both Samsung Biologics and GreenLight are committed to vaccine equity and envision a world capable of producing enough messenger RNA vaccine doses for billions of people each year. This supports GreenLight’s quest to vaccinate the world against COVID-19, as detailed in its Blueprint To Vaccinate The World, published in March 2021. not just for COVID-19 but other infectious diseases that reflect ongoing global health needs.

“We are excited to be working with Samsung to produce messenger RNA for our Covid vaccine study. There is an urgent need to develop vaccines for the whole world, ”said GreenLight CEO Andrey Zarur. “Our vaccine study will pave the way for making vaccines available to everyone, not just citizens of developed countries.”

“We are excited to partner with GreenLight to leverage our expertise in manufacturing a messenger RNA COVID-19 vaccine candidate to better serve patients in low-income countries,” said John Rim, CEO of Samsung Biologics. “This collaboration represents an important milestone for Samsung Biologics as we will begin our expanded capabilities and activities to provide end-to-end messenger RNA production from a single source, from active ingredient substance (DS) to aseptic fill finish (DP ) from a single location until commercial release. In this time of urgent global demand, we will seek seamless service across our bioproduction network to combat the COVID pandemic and in turn help advance the Korean vaccine hub goal. “

Samsung Biologics has been proactively addressing customer needs in the CDMO biopharmaceutical landscape, including its plans to expand the current Songdo facility with the manufacture of Messenger RNA Vaccine Active Substances (DS) scheduled for the beginning of 2022 cGMP operations are ready.

About GreenLight

Founded in 2008, GreenLight aims to solve some of the world’s biggest problems by realizing the full potential of RNA for human health and agriculture. In human health, this includes messenger RNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a number of crops. The company’s pioneering cell-free dsRNA production platform, which is protected by numerous patents, enables cost-effective and scalable production of RNA. For more information, visit

In August 2021GreenLight Biosciences announced plans to enter into a business combination with Environmental Impact Acquisition Corp. (Nasdaq:ENVI).

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO that offers state-of-the-art contract development, manufacturing and laboratory testing. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and uniquely able to support the development and manufacture of biologics products at every stage of the process while meeting the evolving needs of the Biopharmaceuticals meet companies worldwide. For more information, visit .

GreenLight forward-looking statements

This press release contains “forward-looking statements” within the meaning of the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995 relating to the proposed transaction between GreenLight Biosciences, Inc. (“GreenLight”) and Environmental Impact Acquisition Corp. (“ENVI”). These forward-looking statements are generally identified by the words “believe”, “project”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “opportunity”, “plan,” ” can ”,“ should ”,“ will ”,“ would ”,“ will be ”,“ will continue ”,“ will likely result ”and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release including, but not limited to, the risk that the Transaction may not be completed in a timely manner or at all, which could adversely affect the price of the securities of ENVI and the impact of the announcement or pendency of the Transaction on the relationships, results of operations, and business of GreenLight in general. Forward-looking statements only apply at the time of their publication. Readers are cautioned not to place undue reliance on forward-looking statements and ENVI and GreenLight undertake no obligation and do not intend to update or revise these forward-looking statements as a result of new information, future events or otherwise.

Samsung Biologics forward-looking statements

This press release contains certain statements that constitute forward-looking statements, including statements that describe the goals, plans, or goals of Samsung Biologics. All of these forward-looking statements and the assumptions on which they are based are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the corresponding forward-looking statements. There can be no guarantee that the results and events contained in the forward-looking statements will actually occur. Except as required by law, Samsung Biologics will not update any forward-looking statements to reflect material developments that may occur after the date of this press release.

GreenLight contact

Thomas Crampton
SVP & Leiter Corporate Affairs
GreenLight Life Sciences
[email protected]
+44 7826 995794
+1 914 202 2762

Samsung Biologics Kontakt
Claire Kim
Senior Director, Global Public Relations
Samsung Biologics
[email protected]

QUELLE Samsung Biologics

similar links


Leave a Reply

Your email address will not be published. Required fields are marked *